Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden

European Heart Journal

Volumn 34, Issue 3, 2013, Pages 177-183

  Davidson, Thomas ^a   Husberg, Magnus ^a   Janzon, Magnus ^a   Oldgren, Jonas ^b   Levin, Lars Åke ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Anticoagulants; Atrial fibrillation; Cost effectiveness; Stroke

Indexed keywords

ANTIVITAMIN K; DABIGATRAN; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SWEDEN; THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; LIFE EXPECTANCY; QUALITY-ADJUSTED LIFE YEARS; STROKE; SWEDEN; WARFARIN;

EID: 84872533774     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs157     Document Type: Article

References (38)

1. Majeed A, Moser K, Carroll K. Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: analysis of data from the general practice research database. Heart 2001;86:284-288.
2. Davidson T, Husberg M, Janzon M, Levin L. The cost of thromboembolic events and its prevention among patients with atrial fibrillation. JAFIB 2011;2:1-11.
3. Ericson L, Bergfeldt L, Björholt I. Atrial fibrillation: the cost of illness in Sweden. Eur J Health Econ 2011;12:479-487.
4. Jönsson L, Eliasson A° , Kindblom J, Almgren O, Edvardsson N. Cost of illness and drivers of cost in atrial fibrillation in Sweden and Germany. Appl Health Econ Health Policy 2010;8:317-325.
5. Berg J, Lindgren P, Nieuwlaat R, Bouin O, Crijns H. Factors determining utility measured with the EQ-5D in patients with atrial fibrillation. Qual Life Res 2010; 19:381-390.
6. Reynolds MR, Lavelle T, Essebag V, Cohen DJ, Zimetbaum P. Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: the Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study. Am Heart J 2006;152:1097-1103.
7. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501.
8. European Society of Cardiology (ESC). Guidelines for the management of atrial fibrillation: The task for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-2429.
9. Connolly S, Ezekowitz M, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly P, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis B, Darius H, Diener H, Joyner C, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Eng J Medicine 2009;361:1139-1151.
10. Connolly S, Ezekowitz M, Yusuf S, Reilly P,Wallentin L. Newly identified events in the RE-LY trial. N Eng J Med 2010;363:1875-1876.
11. Connolly S, Ezekowitz M, Yusuf S, Reilly P,Wallentin L. Supplementary appendix-newly identified events in the RE-LY trial. N Eng J Med 2010;363:1875-1876.
12. Drummond M, Sculpher M, Torrance G, O'Brien B, Stoddart G. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford university press; 2005.
13. Swedish Pharmaceutical Benefits Board (Läkemedelsförma° nsnämnden). General Guidelines for Economic Evaluations. Stockholm: Pharmaceutical Benefits Board; 2003.
14. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke-Results from the national registry of atrial fibrillation. JAMA 2001;285:2864-2870.
15. Ghatnekar O, Persson U, Glader E, Terént A. Cost of stroke in Sweden: an incidence estimate. Int J Tech Ass Health Care 2004;20:375-380.
16. Brüggenjürgen B, Rossnagel K, Roll S, Andersson F, Selim D, Müller-Nordhorn J, Nolte C, Jungehülsing G, Villringer A, Willich S. The impact of atrial fibrillation on the cost of stroke: the Berlin acute stroke study. Value Health 2007;10:137-143.
17. Luengo-Fernandez R, Gray A, Rothwell P. Population-based study of determinants of initial secondary care costs of acute stroke in the United Kingdom. Stroke 2006; 37:2579-2587.
18. O'Brien C, Gage B. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA 2005;293:699-706.
19. Cameron C, van Zanten S, Skedgel C, Flowedew G, Moayyedi P, Sketris I. Cost-utility analysis of proton pump inhibitor and other gastro-protective agents for prevention of gastrointestinal complications in elderly patients taking non-selective non-steroidal anti-inflammatory agents. Aliment Pharmacol Ther 2010;31:1354-1364.
20. Janzon M. Treatment strategies in unstable coronary artery disease economic and quality of life evaluations. Linköping Medical Dissertation No 811: Linköping 2003.
21. Oldgren J, Alings M, Darius H, Diener H, Eikelboom J, Ezekowitz M, Kamensky G, Reilly P, Yang S, Yusuf S, Wallentin L, Connolly S. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med 2011;155:660-667.
22. Wallentin L, Yusuf S, Ezekowitz M, Alings M, Flather M, Grazia Franzosi M, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly P, Yang S, Connolly S. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975-983.
23. Dolan P. Modeling valuations for EuroQol Health states. Med Care 1997;35: 1095-1098.
24. Burström K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 2001;10:621-635.
25. Lee H, Hwang J, Jeng J, Wang J. Quality-adjusted life expectancy (QALE) and loss of QALE for patients with ischemic stroke and intracerebral hemorrhage. A 13-year follow-up. Stroke 2010;41:739-744.
26. Burström K, Johannesson M, Diderichsen F. Health related quality of life by disease and socio-economic group in the general population in Sweden. Health Policy 2001;55:51-69.
27. Statistics Sweden. 2010; http://www.scb.se/Pages/TableAndChart-262459 .aspx (30 December 2010).
28. Henriksson K, Farahmand B, Johansson S,A° sberg S, Terént A, Edvardsson N. Survival after stroke-the impact of CHADS2 score and atrial fibrillation. Int J Cardiol 2010;141:18-23.
29. Gage B, Cardinalli A, Owens D. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med 1996;156:1829-1836.
30. Svensson P. Patient preference and willingness-to-pay among different oral anticoagulant treatment options. Poster in ihe International Society on Thrombosis & Haemostasis (ISTH) Congress, 2005. Poster.
31. Ekman M. Studies in Health Economics-Modelling and Data Analysis of Costs and Survival. Stockholm: Stockholm school of economics; 2002.
32. Freeman J, Zhu R, Owens D, Garber A, Hutton D, Go A, Wang P, Turakhia M. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011;154:1-11.
33. Kamel H, Johnston S, Easton J, Kim A. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke 2012;43:881-883.
34. Pink J, Lane S, Pirmohamed M, Hughes D. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ 2011;343:d6333.
35. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 2011;123:2562-2570.
36. Sorensen S, Kansal A, Connolly S, Peng S, Linnehan J, Bradley-Kennedy C, Plumb J. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective. Thromb Haemost 2011;105:908-919.
37. Freeman J, Turakhia M. Dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011;154:570-571.
38. Friberg L, Hammar N, Ringh M, Pettersson H, Rosenqvist M. Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on atrial fibrillation (SCAF-study). Eur Heart J 2006;27:1954-1964.